US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

9.14

+0.06000.66%

Post-market: 9.250.1100+1.20%19:30 EDT

Volume:338.52K

Turnover:3.09M

Market Cap:731.10M

PE:-1.56

High:9.36

Open:9.10

Low:8.80

Close:9.08

52wk High:14.87

52wk Low:7.00

Shares:79.99M

Float Shares:35.75M

Volume Ratio:1.14

T/O Rate:0.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.8439

EPS(LYR):-4.3039

ROE:-81.92%

ROA:-47.10%

PB:2.26

PE(LYR):-2.12

Loading ...

Overview Company News Filings

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

BridgeBio Oncology wins FDA fast-track for BBO-11818 in KRAS-mutant pancreatic cancer

BridgeBio Oncology Therapeutics Inc: Updated Phase 1 Clinical Data Are Expected in Second Half of 2026

THOMSON REUTERS

Bbot Granted U.S. FDA Fast Track Designation for Bbo-11818 for the Treatment of Adult Patients With Advanced Kras-Mutant Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS

BridgeBio Oncology Therapeutics grants inducement stock options for 32,675 shares at $8.4

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board; board size increases to nine directors

BridgeBio Oncology Therapeutics to present research at AACR Annual Meeting 2026

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Wedbush Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility

BridgeBio Oncology announces publication of preclinical data on BBO-11818

BBOT Advances BBO-11818 in Phase 1 KONQUER-101 Trial for KRAS-Mutant Solid Tumors

BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Oppenheimer

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Omada Health, Inc. (OMDA) and BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Is Maintained at Buy by HC Wainwright & Co.

BridgeBio Oncology Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate

Benzinga Earnings

BBOT FY 2025 G&A expenses rise 3.2x to USD 24.6 million

BridgeBio Oncology Therapeutics Inc: Qtrly EPS $-0.49

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BBOT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":9.14,"timestamp":1787601600000,"preClose":9.08,"halted":0,"volume":338518,"hourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.14,"latestTime":"19:30 EDT","volume":7478,"amount":68439.12,"timestamp":1787614207210,"change":0.11,"changeRate":0.012035,"amplitude":0.012035},"delay":0,"changeRate":0.006607929515418557,"floatShares":35752400,"shares":79988687,"eps":-5.843879,"marketStatus":"Closed","change":0.06,"latestTime":"08-24 16:00:00 EDT","open":9.1,"high":9.3575,"low":8.8,"amount":3089191.70893,"amplitude":0.061399,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.843879,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":9.08,"preHourTrading":{"tag":"盘前","latestPrice":9.14,"preClose":9.08,"latestTime":"09:02 EDT","volume":12,"amount":109.80000000000001,"timestamp":1787576550596,"change":0.06,"changeRate":0.006608,"amplitude":0.002203},"postHourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.14,"latestTime":"19:30 EDT","volume":7478,"amount":68439.12,"timestamp":1787614207210,"change":0.11,"changeRate":0.012035,"amplitude":0.012035},"volumeRatio":1.139074},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":35752400,"roa":"-47.10%","roe":"-81.92%","lyrEps":-4.3039,"volumeRatio":1.139074,"shares":79988687,"dividePrice":0,"high":9.3575,"amplitude":0.061399,"preClose":9.08,"low":8.8,"week52Low":7,"pbRate":"2.26","week52High":14.87,"institutionHeld":0,"latestPrice":9.14,"eps":-5.843879,"divideRate":0,"volume":338518,"delay":0,"ttmEps":-5.843879,"open":9.1,"prevYearClose":12.52,"prevWeekClose":9.08,"prevMonthClose":8.09,"prevQuarterClose":7.62,"fiveDayClose":9.04,"twentyDayClose":8.75,"sixtyDayClose":8.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BBOT","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-05-12","symbol":"BBOT","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.53},{"market":"US","date":"2026-03-05","symbol":"BBOT","fiscalQuarterEnding":"2025/12","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.6364,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1783742400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2026-08-21","current":-1.56403,"percent":0.948413,"low":-11.944957,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"high":-3.70137,"avg":-7.183327,"sd":2.49794,"marketCap":727982344},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621},{"date":"2025-12-26","current":-8.490629,"twenty":-11.051335,"median":-9.938056,"eighty":-8.720294,"marketCap":975861981},{"date":"2026-01-02","current":-8.713334,"twenty":-11.00789,"median":-9.919954,"eighty":-8.650698,"marketCap":1001458361},{"date":"2026-01-09","current":-9.256178,"twenty":-10.960825,"median":-9.809862,"eighty":-8.597806,"marketCap":1063849537},{"date":"2026-01-16","current":-8.003462,"twenty":-10.901088,"median":-9.61327,"eighty":-8.567184,"marketCap":919869900},{"date":"2026-01-23","current":-7.829474,"twenty":-10.885701,"median":-9.557912,"eighty":-8.530995,"marketCap":899872728},{"date":"2026-01-30","current":-8.699415,"twenty":-10.880305,"median":-9.521034,"eighty":-8.553265,"marketCap":999858587},{"date":"2026-02-06","current":-7.063925,"twenty":-10.867923,"median":-9.470009,"eighty":-8.485061,"marketCap":811885173},{"date":"2026-02-13","current":-7.947786,"twenty":-10.83411,"median":-9.398729,"eighty":-8.38554,"marketCap":913470805},{"date":"2026-02-20","current":-7.043047,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"marketCap":809485512},{"date":"2026-02-27","current":-7.13352,"twenty":-10.763512,"median":-9.179623,"eighty":-8.144045,"marketCap":819884041},{"date":"2026-03-06","current":-6.882977,"twenty":-10.695084,"median":-9.036987,"eighty":-8.006246,"marketCap":791088114},{"date":"2026-03-13","current":-5.451193,"twenty":-10.678337,"median":-8.936039,"eighty":-7.945698,"marketCap":730699673},{"date":"2026-03-20","current":-5.403428,"twenty":-10.588779,"median":-8.821207,"eighty":-7.854528,"marketCap":724297048},{"date":"2026-03-27","current":-5.510899,"twenty":-10.477499,"median":-8.762051,"eighty":-7.489849,"marketCap":738702956},{"date":"2026-04-02","current":-5.391486,"twenty":-10.453966,"median":-8.733947,"eighty":-7.421645,"marketCap":722696391},{"date":"2026-04-10","current":-5.287,"twenty":-10.379747,"median":-8.713334,"eighty":-7.088979,"marketCap":708690647},{"date":"2026-04-17","current":-5.504928,"twenty":-10.361645,"median":-8.657658,"eighty":-7.020776,"marketCap":737902628},{"date":"2026-04-24","current":-5.355662,"twenty":-10.30763,"median":-8.605462,"eighty":-6.799463,"marketCap":717894422},{"date":"2026-05-01","current":-5.021307,"twenty":-10.25963,"median":-8.567184,"eighty":-5.98855,"marketCap":673076041},{"date":"2026-05-08","current":-4.692922,"twenty":-10.225879,"median":-8.553265,"eighty":-5.587323,"marketCap":629057988},{"date":"2026-05-15","current":-4.419866,"twenty":-10.182434,"median":-8.490629,"eighty":-5.506122,"marketCap":681079323},{"date":"2026-05-22","current":-4.73149,"twenty":-10.167401,"median":-8.47671,"eighty":-5.429101,"marketCap":729099017},{"date":"2026-05-29","current":-4.595521,"twenty":-10.107271,"median":-8.403635,"eighty":-5.355662,"marketCap":708146799},{"date":"2026-06-05","current":-4.278409,"twenty":-10.091924,"median":-8.379277,"eighty":-5.319839,"marketCap":659281465},{"date":"2026-06-12","current":-3.878121,"twenty":-10.077631,"median":-8.309681,"eighty":-5.287,"marketCap":597598995},{"date":"2026-06-18","current":-3.992489,"twenty":-10.053919,"median":-8.201809,"eighty":-5.246997,"marketCap":615222558},{"date":"2026-06-26","current":-3.997687,"twenty":-9.989006,"median":-8.066098,"eighty":-5.177737,"marketCap":616023629},{"date":"2026-07-02","current":-4.054871,"twenty":-9.965147,"median":-8.010422,"eighty":-5.018919,"marketCap":624835411},{"date":"2026-07-10","current":-4.725485,"twenty":-9.946462,"median":-7.965184,"eighty":-4.959212,"marketCap":728173575},{"date":"2026-07-17","current":-4.319998,"twenty":-9.932881,"median":-7.944306,"eighty":-4.729088,"marketCap":665690034},{"date":"2026-07-24","current":-4.533138,"twenty":-9.923745,"median":-7.895589,"eighty":-4.678698,"marketCap":698533946},{"date":"2026-07-31","current":-4.41877,"twenty":-9.900032,"median":-7.829474,"eighty":-4.589283,"marketCap":680910384},{"date":"2026-08-07","current":-4.56433,"twenty":-9.857488,"median":-7.544133,"eighty":-4.574377,"marketCap":703340373},{"date":"2026-08-14","current":-4.060031,"twenty":-9.815588,"median":-7.439739,"eighty":-4.568002,"marketCap":739388569},{"date":"2026-08-21","current":-3.997399,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"marketCap":727982344}],"updateTime":1787617312855},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629774458","title":"Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT","url":"https://stock-news.laohu8.com/highlight/detail?id=2629774458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629774458?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:55","pubTimestamp":1776725700,"startTime":"0","endTime":"0","summary":"Amazon said it would invest $5 billion in Anthropic, with the potential for up to $20 billion more based on commercial milestones. Anthropic also committed to spend upward of $100 billion on Amazon technologies over the next ten years. Shares gained 2.6% to $254.80 in after-hours trading Monday.Alaska Air Group withdrew its guidance, citing uncertainty around the cost of fuel from the war in Iran. Shares fell 4.9% to $41.40 after the bell.BridgeBio Oncology Therapeutics received fast-track designation from the Food and Drug Administration for its pancreatic cancer treatment. Shares were up 4.2% to $9.65.AXT disclosed plans to sell shares in a secondary offering. The stock declined 12% to $69.25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMZN","SG9999014898.SGD","IE00BWXC8680.SGD","BK4548","LU1066051811.HKD","LU2023251221.USD","LU1861127337.USD","LU1069344957.HKD","LU0390134368.USD","LU1201861165.SGD","LU0708995401.HKD","LU0133085943.USD","LU2505996509.AUD","LU0708994859.HKD","LU2247934214.USD","AMZD","LU1691799644.USD","LU0011850046.USD","IE00B19Z3581.USD","IE0009356076.USD","LU2106854487.HKD","LU1674673428.USD","IE000F7OJYX1.SGD","LU2065171311.SGD","LU0158827781.USD","LU1852331112.SGD","LU0130102774.USD","LU1084165304.USD","LU0345768153.USD","LU2326559502.SGD","LU2125154935.USD","LU1883839398.USD","LU2237957811.SGD","LU2552382215.SGD","LU2023250504.SGD","LU1880398471.USD","LU1127390331.HKD","IE00BZ1G4Q59.USD","BK4008","LU0342679015.USD","SG9999015978.USD","LU2750360641.GBP","LU1046421795.USD","SG9999002224.SGD","LU0175139822.USD","LU1868837136.USD","LU0127658192.USD","LU2756315318.SGD","LU2168564495.EUR","LU2275660780.HKD","LU0683600562.USD","LU1496350171.SGD","LU0345768740.USD","LU2242649171.HKD","LU1868836757.USD","LU2264538146.SGD","BK4535","LU0353189680.USD","LU0648000940.SGD","LU1551013425.SGD","LU2242650005.HKD","BK4588","IE000W1ABFV2.USD","HK0000914660.USD","LU1934455863.HKD","LU1868837300.USD","SG9999014906.USD","LU2023250843.SGD","IE00B7KXQ091.USD","LU2505996681.GBP","LU1066051498.USD","LU0072461881.USD","LU1267930490.SGD","LU1037948897.HKD","LU1804176565.USD","LU2087625088.SGD","LU0082616367.USD","LU1839511570.USD","LU2168564222.USD","LU1674673691.USD","SG9999014914.USD","LU2417539215.USD","IE00B19Z3B42.SGD","LU1116320737.USD","BK4612","LU2092627202.USD","LU2089283258.USD","AZYY","GOOG","META","IE000KEQY171.SGD","IE00B3S45H60.SGD","LU0215105999.USD","LU0820561909.HKD","BK4524","LU2756315664.SGD","LU0289941410.SGD","IE00B5949003.HKD","ALK","LU0640476718.USD","LU0965509101.SGD","LU1244550221.USD","IE00BQXX3F31.USD","LU0208291251.USD","LU0310800379.SGD","IE00BKDWB100.SGD","IE000BZT7R73.USD","LU0077335932.USD","LU1116320901.HKD","IE00B19Z8W00.USD","LU0251132253.USD","LU2452424414.USD","IE00BJJMRX11.SGD","LU0320765489.SGD","BK4554","LU0302445910.USD","LU0061474705.USD","LU0345770308.USD","LU1551013342.USD","IE00BK4W5M84.HKD","LU0724617625.USD","IE00BMPRXQ63.HKD","LU2360032135.SGD","LU2487616109.SGD","LU1153585028.USD","IE00B19Z8X17.USD","LU1868836914.USD","LU2108987350.USD","SG9999018857.SGD","BBOT","LU2602419157.SGD","LU0203202063.USD","LU2462591350.SGD","LU1880398554.USD","LU0316494557.USD","LU1066051225.USD","IE00B7SZLL34.SGD","LU0314104364.USD","LU0097036916.USD","USAW.SI","LU1267930573.SGD","LU0170899867.USD","LU0203201768.USD","LU1814569148.SGD","TSLA","IE000SO60NU8.SGD","LU0061475181.USD","LU2462157665.USD","IE0000B7K699.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU0823434583.USD","LU2089284900.SGD","IE000ITXATA3.USD","LU2063271972.USD","LU1989764748.USD","LU0312595415.SGD","IE00BQXX3C00.GBP","LU0964807845.USD","AXTI","LU1815333072.USD","AMZW","LU0823421333.USD","LU1868836591.USD","LU0128525929.USD","LU2361044865.SGD","LU2430703251.USD","LU0788109477.HKD","LU2236285917.USD","LU2552382058.USD","IE0004086264.USD","LU0096362180.USD","SG9999015945.SGD","BK4592","LU1429558221.USD","LU0198837287.USD","IE00BMPRXR70.SGD","LU2213496289.HKD","LU0320765059.SGD","AMZP","LU1791710582.SGD","BK4533","LU0861579265.USD","SGXZ99366536.SGD","LU2237957902.USD","GB00BDT5M118.USD","HK0000304805.HKD","IE000WAW04H5.SGD","LU2211815571.USD","LU2237438978.USD","LU0823411888.USD","LU0238689110.USD","LU1914381329.SGD","IE0034235303.USD","LU0256863902.USD","LU2065169927.USD","LU0211327993.USD","LU2092937148.SGD","LU1861559042.SGD","AMZZ","LU1791710400.SGD","IE00BJJMRY28.SGD","BK4538","LU0823421416.USD","LU2250418816.HKD","LU1064131342.USD","IE00B19Z9505.USD","LU2720916845.USD","LU2456880835.USD","SG9999015986.USD","LU1119994496.HKD","LU1778281490.HKD","LU2111349929.HKD","LU0157215616.USD","IE00BJTD4N35.SGD","LU2764263039.SGD","SG9999000418.SGD","SG9999015952.SGD","HK0000532082.HKD","LU0310799852.SGD","IE00BYQQ9H92.USD","IE00B4YYXB79.USD","LU0056508442.USD","LU1629891620.HKD","LU2065171402.SGD","LU1974910355.USD","LU0308772762.SGD","LU1037948541.HKD","IE0004445015.USD","LU2471134879.HKD","LU1803068979.SGD","LU0943347566.SGD","LU0070302665.USD","LU0149725797.USD","LU2430703178.SGD","LU0130103400.USD","LU2471134952.CNY","AMZU","LU1323610961.USD","LU0719512351.SGD","LU1496350502.SGD","BK4220","LU0345770993.USD","LU2420271590.USD","LU0080751232.USD","LU0354030438.USD","LU2764263203.CNY","LU1261432733.SGD","NVDA","IE00BKPKM429.USD","LU0072462426.USD","IE0003U64NQ7.SGD","SG9999001077.SGD","LU0070217475.USD","LU0957791311.USD","BK4581","LU2211817866.USD","LU0210536198.USD","LU2168564149.EUR","LU2271345857.HKD","LU1435385759.SGD","LU2097829019.USD","LU2592432038.USD","LU2168563687.JPY","LU1935043536.SGD","LU2265009873.SGD","IE00B5TLWC47.USD","LU2360106780.USD","LU2362541273.HKD","LU2552382132.HKD","SG9999004303.SGD","BK4559","BK4566","HK0000304797.USD","LU2471134523.USD","LU0048584097.USD","LU0672654240.SGD","AAPL","LU2054465674.USD","SG9999017495.SGD","LU0417517546.SGD","LU1366192091.USD","BK4532","LU0096364046.USD","BK4561","BK4604","LU0965508806.USD","SGXZ81514606.USD","LU0345769631.USD","LU2463028550.USD","LU2746668974.SGD","BK4585","LU0820561818.USD","LU2461242641.AUD","LU2362540622.SGD","LU1720051108.HKD","IE0009G5SDU7.USD","LU0079474960.USD","LU0345774631.USD","LU2087621335.USD","LU1066053197.SGD","LU1548497426.USD","IE00BJLML261.HKD","LU1935042991.SGD","LU1280957306.USD","LU2125154778.USD","LU0345769128.USD","LU1074936037.SGD","LU0107464264.USD","IE0005OL40V9.USD","IE000MB6IJN5.SGD","LU0174119429.USD","LU1718418525.SGD","LU0234572021.USD","BK4598","LU1935042215.USD","LU0138981039.USD","BK4527","BK4551","AMZY","LU0528227936.USD","LU2543165471.USD","LU0787776722.HKD","SGXZ51526630.SGD","LU0265550946.USD","LU1244550494.USD","LU0210533765.USD","IE00BJTD4V19.USD","IE00BKVL7J92.USD","LU2028103732.USD","LU0323591593.USD","LU2361045086.USD","LU0109392836.USD","LU1917777945.USD","LU1934455277.USD","IE00B1XK9C88.USD","LU1267930730.SGD","LU0109391861.USD","SG9999014880.SGD","LU0348723411.USD","LU0353189763.USD","LU1366333091.USD","LU0823434740.USD","LU0965509283.SGD","HK0000914686.HKD","LU0158827948.USD","LU1823568750.SGD","BK4534","LU1989764664.SGD","LU0029864427.USD","LU0689472784.USD","LU1145028129.USD","LU1988902786.USD","LU2746668461.USD","LU0820562030.AUD","IE00B3SWFQ91.USD","LU2357305700.SGD","BK4596","LU0882574139.USD","SGXZ23171101.USD","LU1244550577.SGD","LU2317271919.USD","LU0265550359.USD","LU0985320562.USD","LU0154236417.USD","LU0289960550.SGD","SGXZ31699556.SGD","LU2362541513.USD","IE00BFXG0V08.USD","LU0267386448.USD","IE00BMPRXN33.USD","LU1935042488.USD","LU0210528500.USD","LU1316542783.SGD","LU0642271901.SGD","LU0466842654.USD","SG9999002232.USD","BK4503","LU1232071149.USD","LU0494093205.USD","LU2750360997.AUD","LU1201861249.SGD","LU2083900584.USD","BK4579","IE0004091025.USD","IE00BN29S564.USD","LU2764262908.HKD","IE0004445239.USD","LU2168564065.EUR","IE00BK4W5L77.USD","BK4500","BK4122","LU0162691827.USD","LU2065170008.USD","LU2896262040.SGD","LU2403377893.USD","LU0061474960.USD","LU0354030511.USD","LU2860962120.EUR","LU2471134796.USD","LU1235294995.USD","IE0002270589.USD","LU0345774391.USD","IE00BFSS8Q28.SGD","BK4139","IE000YTNTUN2.SGD","IE00BQXX3D17.EUR","SG9999018865.SGD","IE00B4JS1V06.HKD","IE00B775H168.HKD","LU2381873111.SGD","BK4550","LU0211328371.USD","LU2077746001.SGD","LU2361044949.HKD","MSFT","LU0980610538.SGD","LU0256863811.USD","IE00BFSS7M15.SGD","LU1035775433.USD","LU2430703095.HKD","LU0053666078.USD","LU0456855351.SGD","BK4507","LU0234570918.USD","LU0889565833.HKD","IE0001KFT4U8.USD","LU1934455194.USD","LU0965509010.AUD","BK4147","LU2023250330.USD","IE00B775SV38.USD","LU1720051017.SGD","LU1935043023.USD","BK4543","LU0786609619.USD","LU1861558580.USD","LU0276348264.USD","LU1633808545.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629177527","title":"BridgeBio Oncology wins FDA fast-track for BBO-11818 in KRAS-mutant pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629177527","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629177527?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:12","pubTimestamp":1776715932,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics received U.S. FDA Fast Track designation for BBO-11818 in adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.Preliminary Phase 1 KONQUER-101 findings were already presented in January 2026, showing an objective tumor response in pancreatic cancer.Early readouts also indicated anti-tumor activity across multiple KRAS-mutant solid tumors, alongside a generally favorable safety profile.Updated Phase 1 clinical data are expected in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL9JvxGn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","BBOT","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","BK4588","LU2210149790.SGD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629677592","title":"BridgeBio Oncology Therapeutics Inc: Updated Phase 1 Clinical Data Are Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629677592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629677592?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:06","pubTimestamp":1776715617,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130TR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377590","title":"Bbot Granted U.S. FDA Fast Track Designation for Bbo-11818 for the Treatment of Adult Patients With Advanced Kras-Mutant Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629377590?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:06","pubTimestamp":1776715617,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130TR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627463400","title":"BridgeBio Oncology Therapeutics grants inducement stock options for 32,675 shares at $8.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2627463400","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627463400?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:06","pubTimestamp":1776110815,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics issued inducement equity awards on April 10, 2026 to one employee hired in March 2026.Award consisted of non-qualified stock options covering 32,675 shares with an exercise price of $8.4.Options vest 25% on first anniversary of employee start date.Remaining options vest in 36 equal monthly installments, subject to continued service.Grants were made under BBOT 2025 Inducement Plan adopted in October 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL1CBcBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","BK4505","SG9999014021.USD","IE00B64PRP62.GBP","BBIO","LU2210149790.SGD","BBOT","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627632954","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627632954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627632954?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:05","pubTimestamp":1776110700,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/13/3272891/0/en/BridgeBio-Oncology-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899007","title":"BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board; board size increases to nine directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899007","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899007?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:53","pubTimestamp":1774558381,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics increased its board size to nine directors and appointed Peter Lebowitz as a Class I director.Peter Lebowitz was also appointed to the Nominating and Corporate Governance Committee and the Compensation Committee.His term expires at the 2026 annual meeting of stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3GDLz4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBOT","BK4505","BK4588","BBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620769264","title":"BridgeBio Oncology Therapeutics to present research at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620769264","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620769264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:07","pubTimestamp":1773864433,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics to present research at AACR Annual Meeting 2026               BridgeBio Oncology will present at the AACR Annual Meeting 2026 on April 17-22, 2026, in San Diego, Califo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL61yzxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4505","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","BBIO","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620026200","title":"BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620026200","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620026200?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:05","pubTimestamp":1773864300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March  18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258586/0/en/BBOT-Announces-Multiple-Presentations-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","BK4512","LU1720051017.SGD","LU1978683503.SGD","LU2298322129.HKD","BK4585","IE00BFMHRM44.USD","LU1548497426.USD","LU0124384867.USD","BK4605","LU1861214812.USD","LU0348723411.USD","BBOT","LU2357305700.SGD","BK4141","LU1861219969.SGD","ON","LU2360107325.USD","BK4107","LU0724618433.USD","LU1720051108.HKD","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU1854103824.USD","BK4117","BK4588","BK4139","LU1861215975.USD","AFG","LU1861220033.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620206574","title":"Wedbush Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206574?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:16","pubTimestamp":1773753367,"startTime":"0","endTime":"0","summary":"In a report released today, David Nierengarten from Wedbush maintained a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $25....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617838652","title":"BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2617838652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617838652?lang=en_us&edition=fundamental","pubTime":"2026-03-07 14:00","pubTimestamp":1772863210,"startTime":"0","endTime":"0","summary":"Bridgebio Oncology Therapeutics, Inc. (BBOT) has disclosed a new risk, in the Innovation / R&D category. The analyst notes that BridgeBio Oncology ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bridgebio-oncologys-narrow-bet-on-kras-and-pi3k-programs-raises-concentration-risk-limits-strategic-flexibility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bridgebio-oncologys-narrow-bet-on-kras-and-pi3k-programs-raises-concentration-risk-limits-strategic-flexibility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617639286","title":"BridgeBio Oncology announces publication of preclinical data on BBO-11818","url":"https://stock-news.laohu8.com/highlight/detail?id=2617639286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617639286?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:26","pubTimestamp":1772810779,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (BBOT) Therapeutics announced the publication of preclinical data describing the discovery and characterization of BBO-11818, a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-announces-publication-of-preclinical-data-on-bbo-11818-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-announces-publication-of-preclinical-data-on-bbo-11818-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617639833","title":"BBOT Advances BBO-11818 in Phase 1 KONQUER-101 Trial for KRAS-Mutant Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617639833","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617639833?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:08","pubTimestamp":1772809711,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. reported that its pan-KRAS inhibitor BBO-11818 is being evaluated in the Phase 1 KONQUER-101 trial  in patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors. Preliminary Phase 1 monotherapy clinical results were previously announced in January 2026, and the company said additional clinical data are expected in the second half of 2026. BBOT also stated that an internal study of BBO-11818 in combination with its RAS:PI3Kα breaker BBO-10203 is anticipated to open later in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDLFx9jF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","BBOT","SG9999014021.USD","SG9999014039.USD","BK4588","IE00B64PRP62.GBP","NDAQ","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD","BK4112","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617802366","title":"BridgeBio Oncology Therapeutics (BBOT) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802366?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:56","pubTimestamp":1772801790,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $22...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bridgebio-oncology-therapeutics-bbot-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bridgebio-oncology-therapeutics-bbot-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BBOT","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617397680","title":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Omada Health, Inc. (OMDA) and BridgeBio Oncology Therapeutics (BBOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617397680","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617397680?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:30","pubTimestamp":1772800213,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), O...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eyepoint-pharmaceuticals-eypt-omada-health-inc-omda-and-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eyepoint-pharmaceuticals-eypt-omada-health-inc-omda-and-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4007","HCSG","BBOT","BK4588","LU0128526141.USD","XBI","BK4137","LU0109394709.USD","LABU","LU0889565916.HKD","OMDA","BK4139","XLV","EYPT","BK4581","BK4585","LU0029874061.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687255","title":"BridgeBio Oncology Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687255","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687255?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:22","pubTimestamp":1772799720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 07:22 ET (12:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617157197","title":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617157197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617157197?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:01","pubTimestamp":1772748089,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryBridgeBio Oncology Therapeutics Inc BBOT.OQ reported a quarterly adjusted loss of 49 cents per s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT2XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4139","BBIO","BBOT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617957653","title":"BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617957653","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617957653?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:10","pubTimestamp":1772745044,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 13.12 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51083316/bridgebio-oncology-q4-eps-0-49-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QYLD","JEPQ","TQQQ","BBOT",".IXIC","GPIQ","QQQJ","SQQQ","QQQY","QYLG","NQmain","QQQE","USJW.SI","TSYW.SI","NVIW.SI","QLD","PSQ","MNQmain","USAW.SI","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575071","title":"BBOT FY 2025 G&A expenses rise 3.2x to USD 24.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575071","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575071?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:07","pubTimestamp":1772744820,"startTime":"0","endTime":"0","summary":"BBOT FY 2025 G&A expenses rise 3.2x to USD 24.6 million               BBOT reported a Q4 2025 net loss of USD 38.8 million and R&D expenses of USD 38.1 million, alongside G&A expenses of USD 5.3 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL2qtNz1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","BBOT","SG9999014005.SGD","LU2095319765.USD","BK4585","LU2210149790.SGD","LU0314104364.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617791205","title":"BridgeBio Oncology Therapeutics Inc: Qtrly EPS $-0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2617791205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617791205?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA64K2XP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}